A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Incyte Corporation
- 25 Jul 2024 Primary endpoint (Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo) has not been met, according to Results published in the BMC Cancer.
- 25 Jul 2024 Results published in the BMC Cancer.
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183887).